New York State Teachers Retirement System Buys 5,689 Shares of TransMedics Group, Inc. $TMDX

Key Points

• The New York State Teachers Retirement System increased its stake in TransMedics Group, Inc. by 25.9%, acquiring an additional 5,689 shares during the second quarter.
• TransMedics Group reported a 37.7% revenue increase year-over-year, with a quarterly revenue of $157.37 million and earnings per share (EPS) of $0.92.
• Currently, TransMedics Group has a consensus rating of "Moderate Buy" among analysts, with price targets ranging from $115.00 to $142.00 per share.

New York State Teachers Retirement System boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 25.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,638 shares of the company's stock after purchasing an additional 5,689 shares during the quarter. New York State Teachers Retirement System owned approximately 0.08% of TransMedics Group worth $3,704,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Atria Wealth Solutions Inc. bought a new position in TransMedics Group in the 2nd quarter worth about $316,000. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $559,000. Total Clarity Wealth Management Inc. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $386,000. Yousif Capital Management LLC raised its holdings in shares of TransMedics Group by 2.2% in the 2nd quarter. Yousif Capital Management LLC now owns 12,908 shares of the company's stock valued at $1,730,000 after acquiring an additional 277 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $286,000. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on TMDX shares. Zacks Research cut TransMedics Group from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $142.00 price target on shares of TransMedics Group in a report on Tuesday, October 14th. Stifel Nicolaus started coverage on TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target on the stock. Finally, Wall Street Zen raised TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $127.18.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $119.90 on Tuesday. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of 62.12 and a beta of 2.08. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $145.50. The stock's 50-day moving average is $116.37 and its 200 day moving average is $114.31.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.